活检前无可疑征象的多参数MRI:前列腺穿刺活检是否仍有必要
本研究回顾性分析2014年1月至2019年3月在本中心接受经直肠超声引导穿刺活检、且活检前多参数MRI无可疑征象(PI-RADS≤2)的191例患者,评估多参数MRI单独或联合PSA密度排除临床显著前列腺癌的阴性预测值。总体前列腺癌和临床显著前列腺癌检出率分别为26.7%和5.2%,阴性预测值分别为73.3%和94.8%;联合PSAd<0.15 ng/mL/cm3时阴性预测值提高至95.8%,PSAd<0.10 ng/mL/cm3时提高至100%。作者认为未来需要研究以平衡该指征下活检的低获益与操作并发症。
要点
- 活检前mpMRI无可疑征象(PI-RADS≤2)时,临床显著前列腺癌的总体阴性预测值为94.8%。
- 联合PSAd<0.15 ng/mL/cm3时阴性预测值提高至95.8%,PSAd<0.10 ng/mL/cm3时提高至100%。
- 总体前列腺癌检出率为26.7%,临床显著前列腺癌检出率为5.2%。
核心结论
- 活检前mpMRI无可疑征象时,单独用于排除临床显著前列腺癌的总体阴性预测值为94.8%,联合PSAd<0.15 ng/mL/cm3时提高至95.8%。
- 作者认为未来需要研究以平衡该指征下活检的低获益与操作并发症。
研究设计与样本
- 回顾性病历审查,纳入本中心2014年1月至2019年3月接受经直肠超声引导穿刺活检的患者。
- 纳入标准为活检前mpMRI无可疑征象,即PI-RADS≤2;共纳入191例连续男性患者,中位年龄65岁,中位PSA水平9.3 ng/mL。
- 191例中活检初治患者126例(66%),既往活检阴性患者36例(18.8%),主动监测下确认性活检患者29例(15.2%)。
- MRI使用1.5或3特斯拉磁共振扫描仪,配备外部相控阵线圈。
- 主要结局为临床显著前列腺癌检出,定义为至少一个穿刺针道Gleason评分3+4(ISUP 2)或更高。
诊断标准与关键数值
- 活检前mpMRI无可疑征象定义为PI-RADS≤2。
- 临床显著前列腺癌定义为至少一个穿刺针道Gleason评分3+4(ISUP 2)或更高。
- 总体前列腺癌检出率为26.7%,临床显著前列腺癌检出率为5.2%,对应阴性预测值分别为73.3%和94.8%。
- PSAd<0.15 ng/mL/cm3时阴性预测值提高至95.8%,PSAd<0.10 ng/mL/cm3时提高至100%。
临床应用与阅片要点
- 活检前mpMRI无可疑征象(PI-RADS≤2)时,临床显著前列腺癌的阴性预测值为94.8%。
- 联合PSAd<0.15 ng/mL/cm3时阴性预测值提高至95.8%,联合PSAd<0.10 ng/mL/cm3时提高至100%。
- 作者认为未来需要研究以平衡该指征下活检的低获益与操作并发症。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To evaluate the negative predictive value (NPV) of multiparametric magnetic resonance imaging (mpMRI), alone or combined with Prostate-Specific Antigen density (PSAd) to exclude clinically significant prostate cancer (csPCa).
PATIENTS AND METHODS: We performed a retrospective chart review of all the patients who had transrectal ultrasound-guided biopsy (TRUSGB) in our center between January 2014 and March 2019. We included patients who had nonsuspicious prebiopsy mpMRI defined as Prostate Imaging-Reporting and Data System (PI-RADS) ≤ 2. MRI was performed using a 1.5 or 3-Tesla Magnetic Resonance scanners with external phased-array coil. The primary outcome was the detection of csPCa, defined as a Gleason score 3 + 4 (ISUP 2) or higher on at least one biopsy core.
RESULTS: One hundred and ninety-one consecutive men (median age: 65 years, median PSA level: 9.3 ng/mL) underwent TRUSGB following negative prebiopsy mpMRI corresponding to 126 (66%) biopsy-naïve patients, 36 (18.8%) patients with prior negative biopsy, and 29 (15.2%) patients under active surveillance with confirmatory biopsies. The overall PCa and csPCA detection rates were 26.7% and 5.2%, conferring a NPV of 73.3% and 94.8%, respectively. The NPV of negative mpMRI improved to 95.8% in patients with PSAd < 0.15 ng/mL/cm3 and to 100% in patients with PSAd < 0.10 ng/mL/cm3.
CONCLUSIONS: A negative prebiopsy mpMRI had an overall NPV of 94.8% for csPCa when mpMRI was used alone to 95.8% when combined with PSAd < 0.15 ng/mL/cm3. Future studies are needed to balance the low benefit of a biopsy in this indication with the morbidity of the procedure.
引用
- Anastay V, Gondran-Tellier B, McManus R, et al. Nonsuspicious prebiopsy multiparametric MRI: is prostate biopsy still necessary? Abdom Radiol (NY). 2020. PMID: 32902661. doi:10.1007/s00261-020-02728-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。